ArticleFrontiers in medicine2026
Integrated single-cell and spatial transcriptomic analyses reveal an aging-associated fibroblast subtype linked to tumor progression in human skin.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- mRNA Therapeutics for Skin Rejuvenation: From Aging Atlases to Clinical Translation.Experimental dermatology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aging is a major risk factor for the development of many cancers, yet the tissue-level mechanisms linking physiological aging to tumor progression remain unclear. Although age-related accumulation of genetic mutations contributes to tumorigenesis, increasing evidence indicates that the aging tissue microenvironment also plays a critical role in shaping cancer susceptibility. In this study, we integrated single-cell RNA sequencing and spatial transcriptomic datasets from healthy human skin and major skin cancers, including melanoma, squamous cell carcinoma, and basal cell carcinoma, to define cell-type-specific aging programs and assess their representation in tumor-associated microenvironments. In healthy skin, aging was associated with widespread but cell-type-specific transcriptional remodeling across epithelial, immune, vascular, and stromal compartments, involving pathways related to inflammation, extracellular matrix organization, and intercellular communication. Projection of these aging signatures into skin cancer datasets revealed that aging-associated programs were not restricted to immune cells but were also prominent in stromal compartments. Age-adjusted survival analysis in melanoma further identified the fibroblast aging program as the most prominent stromal signature, with higher program activity being associated with poor patient outcomes, motivating a focused analysis of fibroblast remodeling in skin cancers. Within this fibroblast-centered framework, we found that SFRP2-expressing fibroblasts accumulated in aged skin and were also enriched in tumor-associated stroma, suggesting that this pre-existing fibroblast state may become incorporated into and potentially support the tumor microenvironment during skin cancer development. Spatial analyses in basal cell carcinoma and squamous cell carcinoma showed that SFRP2-associated fibroblast signals were enriched near tumor-associated regions and WNT-active niches. Additional spatial proxy analyses and expression profiling of matrix-remodeling and growth factor-related genes further supported the association of this fibroblast state with tumor-associated stromal remodeling. Together, our findings suggest that aging-associated fibroblast remodeling may contribute to a tumor-permissive skin microenvironment and provide a framework for understanding how aging tissue ecosystems influence skin cancer progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.